Login Register Cart 0
Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Second-line Therapy for Helicobacter Pylori Eradication: State of the Art

Author(s): Giuseppe Losurdo*, Fulvio Salvatore D’Abramo, Mariapaola Piazzolla, Raffaella Rima, Antonio Continisio, Maria Pricci, Enzo Ierardi and Alfredo Di Leo

Volume 22, Issue 19, 2022

Published on: 23 May, 2022

Page: [2430 - 2437] Pages: 8

DOI: 10.2174/1389557522666220325153832

Price: $65

Abstract

Helicobacter pylori (H. pylori) is a Gram negative spiraliform bacterium that colonizes the human stomach. It is the most common cause of chronic gastritis, peptic ulcer, and gastric carcinoma. The eradication therapy is based on the combination of a proton pump inhibitor and several antibiotics such as amoxicillin, metronidazole, clarithromycin, levofloxacin or tetracycline. The most commonly used regimens for eradication in the first line are triple, sequential and concomitant therapy, despite the last European Guidelines suggesting a quadruple therapy already at the first attempt in areas with high resistance rates. However, the rise in antibiotic resistance is the main reason for a marked increase in first-line therapy failure. Clarithromycin resistancea, is especially acknowledged as the most important event resulting in failure. Up to 20% of patients are intended not to eradicate, therefore they will need a second line therapy. Currently, the most used rescue regimens are levofloxacin-based triple therapy and bismuth-containing quadruple therapy, despite guidelines suggesting to use a combination of antibiotics that have not been included in previous treatments. Nitazoxanide is a novel antibiotic with promising results. Additionally, an interesting field worth of investigation is the antibiotic susceptibility based approach, which could help choose antibiotics with confirmed effectiveness in vitro. Analysis of antibiotic resistance may be performed by both bacterial culture and molecular biology techniques, able to detect point mutations conferring resistance. This is a particularly interesting approach, since it may personalize the therapy, thus optimizing the regimen and maximizing the probability of success.

Keywords: Helicobacter pylori, therapy, eradication, rescue, levofloxacin, tetracycline, antibiotics.

« Previous Next »
Graphical Abstract

[1]
Hooi, J.K.Y.; Lai, W.Y.; Ng, W.K.; Suen, M.M.Y.; Underwood, F.E.; Tanyingoh, D.; Malfertheiner, P.; Graham, D.Y.; Wong, V.W.S.; Wu, J.C.Y.; Chan, F.K.L.; Sung, J.J.Y.; Kaplan, G.G.; Ng, S.C. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology, 2017, 153(2), 420-429.
[http://dx.doi.org/10.1053/j.gastro.2017.04.022] [PMID: 28456631]
[2]
Li, J.; Perez-Perez, G.I. Helicobacter pylori the latent human pathogen or an ancestral commensal organism. Front. Microbiol., 2018, 9, 609.
[http://dx.doi.org/10.3389/fmicb.2018.00609] [PMID: 29666614]
[3]
Nair, M.R.; Chouhan, D.; Sen Gupta, S.; Chattopadhyay, S. Fermented foods: Are they tasty medicines for Helicobacter pylori associated peptic ulcer and gastric cancer? Front. Microbiol., 2016, 7, 1148.
[4]
Sugano, K.; Tack, J.; Kuipers, E.J.; Graham, D.Y.; El-Omar, E.M.; Miura, S.; Haruma, K.; Asaka, M.; Uemura, N.; Malfertheiner, P. Kyoto global consensus report on Helicobacter pylori gastritis. Gut, 2015, 64(9), 1353-1367.
[http://dx.doi.org/10.1136/gutjnl-2015-309252] [PMID: 26187502]
[5]
Plummer, M.; Franceschi, S.; Vignat, J.; Forman, D.; de Martel, C. Global burden of gastric cancer attributable to Helicobacter pylori. Int. J. Cancer, 2015, 136(2), 487-490.
[http://dx.doi.org/10.1002/ijc.28999] [PMID: 24889903]
[6]
Zagari, R.M.; Romano, M.; Ojetti, V.; Stockbrugger, R.; Gullini, S.; Annibale, B.; Farinati, F.; Ierardi, E.; Maconi, G.; Rugge, M.; Calabrese, C.; Di Mario, F.; Luzza, F.; Pretolani, S.; Savio, A.; Gasbarrini, G.; Caselli, M. Guidelines for the management of Helicobacter pylori infec-tion in Italy: The III working group consensus report 2015. Dig. Liver Dis., 2015, 47(11), 903-912.
[http://dx.doi.org/10.1016/j.dld.2015.06.010] [PMID: 26253555]
[7]
Nakamura, S.; Sugiyama, T.; Matsumoto, T.; Iijima, K.; Ono, S.; Tajika, M.; Tari, A.; Kitadai, Y.; Matsumoto, H.; Nagaya, T.; Kamoshida, T.; Watanabe, N.; Chiba, T.; Origasa, H.; Asaka, M. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helico-bacter pylori: A multicentre cohort follow-up study of 420 patients in Japan. Gut, 2012, 61(4), 507-513.
[http://dx.doi.org/10.1136/gutjnl-2011-300495] [PMID: 21890816]
[8]
Malfertheiner, P.; Megraud, F.; O’Morain, C.A.; Gisbert, J.P.; Kuipers, E.J.; Axon, A.T.; Bazzoli, F.; Gasbarrini, A.; Atherton, J.; Graham, D.Y.; Hunt, R.; Moayyedi, P.; Rokkas, T.; Rugge, M.; Selgrad, M.; Suerbaum, S.; Sugano, K.; El-Omar, E.M. Management of Helicobacter pylori infection‐the Maastricht V/Florence consensus report. Gut, 2017, 66(1), 6-30.
[http://dx.doi.org/10.1136/gutjnl-2016-312288] [PMID: 27707777]
[9]
Thung, I.; Aramin, H.; Vavinskaya, V.; Gupta, S.; Park, J.Y.; Crowe, S.E.; Valasek, M.A. Review article: The global emergence of Helico-bacter pylori antibiotic resistance. Aliment. Pharmacol. Ther., 2016, 43(4), 514-533.
[http://dx.doi.org/10.1111/apt.13497] [PMID: 26694080]
[10]
Argueta, E.A.; Alsamman, M.A.; Moss, S.F.; D’Agata, E.M. Impact of antimicrobial resistance rates on eradication of Helicobacter pylori in a US population. Gastroenterology, 2021, 160 6, 2181-2183.
[http://dx.doi.org/10.1053/j.gastro.2021.02.014]
[11]
Megraud, F.; Bruyndonckx, R.; Coenen, S.; Wittkop, L.; Huang, T.D.; Hoebeke, M.; Bénéjat, L.; Lehours, P.; Goossens, H.; Glupczynski, Y. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut, 2021, 70(10), 1815-1822.
[http://dx.doi.org/10.1136/gutjnl-2021-324032] [PMID: 33837118]
[12]
Losurdo, G.; Giorgio, F.; Pricci, M. Helicobacter pylori primary and secondary genotypic resistance to clarithromycin and levofloxacin detection in stools: A 4-year scenario in Southern Italy. Antibiotics, 2020. 9.10, 723.
[13]
Chey, W.D.; Leontiadis, G.I.; Howden, C.W.; Moss, S.F. ACG clinical guideline: Treatment of Helicobacter pylori infection. Am. J. Gastroenterol., 2017, 112(2), 212-239.
[http://dx.doi.org/10.1038/ajg.2016.563] [PMID: 28071659]
[14]
Gong, Y.; Yuan, Y. Resistance mechanisms of Helicobacter pylori and its dual target precise therapy. Crit. Rev. Microbiol., 2018, 44(3), 371-392.
[http://dx.doi.org/10.1080/1040841X.2017.1418285] [PMID: 29293032]
[15]
Van Boeckel, T.P.; Gandra, S.; Ashok, A. Global antibiotic consumption 2000 to 2010: An analysis of national pharmaceutical sales data. Lancet, 2014, 14(8), 742-750.
[16]
Shah, S.C.; Iyer, P.G.; Moss, S.F. AGA clinical practice update on the management of refractory Helicobacter pylori infection: Expert re-view. Gastroenterology, 2021, 160(5), 1831-1841.
[http://dx.doi.org/10.1053/j.gastro.2020.11.059] [PMID: 33524402]
[17]
Lee, M.; Kemp, J.A.; Canning, A.; Egan, C.; Tataronis, G.; Farraye, F.A. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch. Intern. Med., 1999, 159(19), 2312-2316.
[http://dx.doi.org/10.1001/archinte.159.19.2312] [PMID: 10547171]
[18]
Ierardi, E.; Losurdo, G.; Giorgio, F.; Iannone, A.; Principi, M.; Di Leo, A. Quinolone-based first, second and third-line therapies for Heli-cobacter pylori. World J. Pharmacol., 2015, 4(4), 274-280.
[http://dx.doi.org/10.5497/wjp.v4.i4.274]
[19]
Lin, T-F.; Hsu, P.I. Second-line rescue treatment of Helicobacter pylori infection: Where are we now? World J. Gastroenterol., 2018, 24(40), 4548-4553.
[http://dx.doi.org/10.3748/wjg.v24.i40.4548] [PMID: 30386104]
[20]
Chen, P-Y.; Wu, M-S.; Chen, C-Y.; Bair, M.J.; Chou, C.K.; Lin, J.T.; Liou, J.M. Systematic review with meta-analysis: The efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment. Pharmacol. Ther., 2016, 44(5), 427-437.
[http://dx.doi.org/10.1111/apt.13712] [PMID: 27363687]
[21]
Di Caro, S.; Fini, L.; Daoud, Y.; Grizzi, F.; Gasbarrini, A.; De Lorenzo, A.; Di Renzo, L.; McCartney, S.; Bloom, S. Levofloxa-cin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J. Gastroenterol., 2012, 18(40), 5669-5678.
[http://dx.doi.org/10.3748/wjg.v18.i40.5669] [PMID: 23155306]
[22]
Gisbert, J.P.; Molina-Infante, J.; Marin, A.C.; Vinagre, G.; Barrio, J.; McNicholl, A.G. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple “sequential” or “concomitant” treatment to eradicate H. pylori infection. Scand. J. Gastroenterol., 2013, 48(6), 652-656.
[http://dx.doi.org/10.3109/00365521.2013.786132] [PMID: 23556551]
[23]
Gisbert, J.P.; Romano, M.; Gravina, A.G.; Solís-Muñoz, P.; Bermejo, F.; Molina-Infante, J.; Castro-Fernández, M.; Ortuño, J.; Lucendo, A.J.; Herranz, M.; Modolell, I.; Del Castillo, F.; Gómez, J.; Barrio, J.; Velayos, B.; Gómez, B.; Domínguez, J.L.; Miranda, A.; Martorano, M.; Algaba, A.; Pabón, M.; Angueira, T.; Fernández-Salazar, L.; Federico, A.; Marín, A.C.; McNicholl, A.G. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment. Pharmacol. Ther., 2015, 41(8), 768-775.
[http://dx.doi.org/10.1111/apt.13128] [PMID: 25703120]
[24]
Marin, A.C.; McNicholl, A.G.; Gisbert, J.P. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helico-bacter pylori eradication). Expert Opin. Pharmacother., 2013, 14(7), 843-861.
[http://dx.doi.org/10.1517/14656566.2013.782286] [PMID: 23537368]
[25]
Marin, A.C.; McNicholl, A.G.; Gisbert, J.P. Efficacy of a second-line levofloxacin-containing triple therapy after the failure of the non-bismuth sequential or concomitant treatments: Systematic review and meta-analysis (abstr P11.39). Helicobacter, 2014, 19(Suppl. 1), 139-140.
[26]
Chuah, S.K.; Tai, W.C.; Hsu, P.I.; Wu, D.C.; Wu, K.L.; Kuo, C.M.; Chiu, Y.C.; Hu, M.L.; Chou, Y.P.; Kuo, Y.H.; Liang, C.M.; Chiu, K.W.; Hu, T.H. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump in-hibitor treatment-a pilot study. Helicobacter, 2012, 17(5), 374-381.
[http://dx.doi.org/10.1111/j.1523-5378.2012.00960.x] [PMID: 22967121]
[27]
Wu, T-S.; Hsu, P-I.; Kuo, C.H.; Hu, H.M.; Wu, I.C.; Wang, S.S.W.; Chen, Y.H.; Wu, D.C.; Su, W.W.; Kuo, F.C. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori. J. Dig. Dis., 2017, 18(9), 537-542.
[http://dx.doi.org/10.1111/1751-2980.12498] [PMID: 28644575]
[28]
Hsu, P-I.; Chen, W-C.; Tsay, F-W.; Shih, C.A.; Kao, S.S.; Wang, H.M.; Yu, H.C.; Lai, K.H.; Tseng, H.H.; Peng, N.J.; Chen, A.; Kuo, C.H.; Wu, D.C. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy. Helicobacter, 2014, 19(1), 74-79.
[http://dx.doi.org/10.1111/hel.12085] [PMID: 24033865]
[29]
Zullo, A.; De Francesco, V.; Hassan, C.; Ridola, L.; Repici, A.; Bruzzese, V.; Vaira, D. Modified sequential therapy regimens for Helico-bacter pylori eradication: A systematic review. Dig. Liver Dis., 2013, 45(1), 18-22.
[http://dx.doi.org/10.1016/j.dld.2012.08.025] [PMID: 23022424]
[30]
Aminian, K.; Farsad, F.; Ghanbari, A.; Fakhreih, S.; Hasheminasab, S.M. A randomized trial comparing four Helicobacter pylori eradica-tion regimens: Standard triple therapy, ciprofloxacin based triple therapy, quadruple and sequential therapy. Trop. Gastroenterol., 2010, 31(4), 303-307.
[PMID: 21568147]
[31]
Aydin, A.; Oruc, N.; Turan, I.; Ozutemiz, O.; Tuncyurek, M.; Musoglu, A. The modified sequential treatment regimen containing levoflo-xacin for Helicobacter pylori eradication in Turkey. Helicobacter, 2009, 14(6), 520-524.
[http://dx.doi.org/10.1111/j.1523-5378.2009.00720.x] [PMID: 19889069]
[32]
Liou, J-M.; Chen, C-C.; Chen, M-J.; Chang, C.Y.; Fang, Y.J.; Lee, J.Y.; Sheng, W.H.; Wang, H.P.; Wu, M.S.; Lin, J.T. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: A multi-centre clinical trial. J. Antimicrob. Chemother., 2011, 66(8), 1847-1852.
[http://dx.doi.org/10.1093/jac/dkr217] [PMID: 21632579]
[33]
Hsu, P-I.; Tsay, F-W.; Kao, J-Y.; Peng, N.J.; Chen, Y.H.; Tang, S.Y.; Kuo, C.H.; Kao, S.S.; Wang, H.M.; Wu, I.T.; Shie, C.B.; Chuah, S.K.; Wu, D.C. Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection. Helicobacter, 2021, 26(5)e12840
[http://dx.doi.org/10.1111/hel.12840] [PMID: 34390083]
[34]
Tai, W.C.; Lee, C.H.; Chiou, S.S.; Kuo, C.M.; Kuo, C.H.; Liang, C.M.; Lu, L.S.; Chiu, C.H.; Wu, K.L.; Chiu, Y.C.; Hu, T.H.; Chuah, S.K. The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication. PLoS One, 2014, 9(8)e105822
[http://dx.doi.org/10.1371/journal.pone.0105822] [PMID: 25141137]
[35]
Fallone, C.A.; Chiba, N.; van Zanten, S.V.; Fischbach, L.; Gisbert, J.P.; Hunt, R.H.; Jones, N.L.; Render, C.; Leontiadis, G.I.; Moayyedi, P.; Marshall, J.K. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology, 2016, 151(1), 51-69.e14.
[http://dx.doi.org/10.1053/j.gastro.2016.04.006] [PMID: 27102658]
[36]
Miehlke, S.; Krasz, S.; Schneider-Brachert, W.; Kuhlisch, E.; Berning, M.; Madisch, A.; Laass, M.W.; Neumeyer, M.; Jebens, C.; Zekorn, C.; Knoth, H.; Vieth, M.; Stolte, M.; Lehn, N.; Morgner, A. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter, 2011, 16(6), 420-426.
[http://dx.doi.org/10.1111/j.1523-5378.2011.00867.x] [PMID: 22059392]
[37]
Nishizawa, T.; Munkjargal, M.; Ebinuma, H.; Toyoshima, O.; Suzuki, H. Sitafloxacin for third-line Helicobacter pylori eradication: A sys-tematic review. J. Clin. Med., 2021, 10(12), 2722.
[http://dx.doi.org/10.3390/jcm10122722] [PMID: 34202993]
[38]
Gisbert, J.P.; McNicholl, A.G. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter, 2017, 22(4)e12392
[http://dx.doi.org/10.1111/hel.12392] [PMID: 28464347]
[39]
Ford, A.C.; Malfertheiner, P. Adverse events with bismuth salts for Helicobacter pylori eradication: Systematic review and meta-analysis. World J. Gastroenterol., 2008, 14(48)
[40]
Alsamman, M.A.; Vecchio, E.C.; Shawwa, K.; Acosta-Gonzales, G.; Resnick, M.B.; Moss, S.F. Retrospective analysis confirms tetracycli-ne quadruple as best Helicobacter pylori regimen in the USA. Dig. Dis. Sci., 2019, 64(10), 2893-2898.
[http://dx.doi.org/10.1007/s10620-019-05694-4] [PMID: 31187323]
[41]
Shin, K.; Cho, M.J.; Oh, J.H. Second-line bismuth-containing quadruple therapy for Helicobacter pylori infection: A 12-year study of annual eradication rates. J. Clin. Med., 2021, 10(15), 3273.
[42]
Kim, J.Y.; Lee, S.Y.; Kim, J.H.; Sung, I.K.; Park, H.S. Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication. Helicobacter, 2020, 25(2)e12683
[http://dx.doi.org/10.1111/hel.12683] [PMID: 32074663]
[43]
Tursi, A.; Franceschi, M.; Allegretta, L.; Savarino, E.; De Bastiani, R.; Elisei, W.; Baldassarre, G.; Ferronato, A.; Scida, S.; Miraglia, C.; Penna, A.; Licci, C.; Rizzo, G.L.; Pranzo, G.; Cassieri, C.; Brandimarte, G.; Picchio, M.; Di Mario, F. Effectiveness and safety of Pylera® in patients infected by Helicobacter pylori: A multicenter, retrospective, real life study. Dig. Dis., 2018, 36(4), 264-268.
[http://dx.doi.org/10.1159/000487391] [PMID: 29669354]
[44]
Nyssen, O.P.; McNicholl, A.G.; Gisbert, J.P. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. Helicobacter, 2019, 24(2)e12570
[http://dx.doi.org/10.1111/hel.12570] [PMID: 30767339]
[45]
Ueki, N.; Miyake, K.; Kusunoki, M.; Shindo, T.; Kawagoe, T.; Futagami, S.; Tsukui, T.; Inagaki, H.; Sakamoto, C. Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure. Helicobacter, 2009, 14(2), 91-99.
[http://dx.doi.org/10.1111/j.1523-5378.2009.00664.x] [PMID: 19298336]
[46]
Hori, K.; Miwa, H.; Matsumoto, T. Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population. Helicobacter, 2011, 16(3), 234-240.
[http://dx.doi.org/10.1111/j.1523-5378.2011.00842.x] [PMID: 21585610]
[47]
Jheng, G.H.; Wu, I.C.; Shih, H.Y.; Wu, M.C.; Kuo, F.C.; Hu, H.M.; Liu, C.J.; Hsu, W.H.; Hu, C.T.; Bair, M.J.; Kuo, C.H.; Wu, D.C.; Hsu, P.I. Comparison of second-line quadruple therapies with or without bismuth for Helicobacter pylori infection. BioMed Res. Int., 2015, 2015163960
[http://dx.doi.org/10.1155/2015/163960] [PMID: 26090383]
[48]
Peitz, U.; Sulliga, M.; Wolle, K.; Leodolter, A.; Von Arnim, U.; Kahl, S.; Stolte, M.; Börsch, G.; Labenz, J.; Malfertheiner, P. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: Impact of two se-cond-line therapies in a randomized study. Aliment. Pharmacol. Ther., 2002, 16(2), 315-324.
[http://dx.doi.org/10.1046/j.1365-2036.2002.01173.x] [PMID: 11860415]
[49]
Lamouliatte, H.; Mégraud, F.; Delchier, J.C.; Bretagne, J.F.; Courillon-Mallet, A.; De Korwin, J.D.; Fauchère, J.L.; Labigne, A.; Fléjou, J.F.; Barthelemy, P. Second-line treatment for failure to eradicate Helicobacter pylori: A randomized trial comparing four treatment strategies. Aliment. Pharmacol. Ther., 2003, 18(8), 791-797.
[http://dx.doi.org/10.1046/j.1365-2036.2003.01759.x] [PMID: 14535872]
[50]
Zhu, Y.J.; Zhang, Y.; Wang, T.Y.; Zhao, J.T.; Zhao, Z.; Zhu, J.R.; Lan, C.H. High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: A systematic review with meta-analysis. Therap. Adv. Gastroenterol., 2020, 131756284820937115
[http://dx.doi.org/10.1177/1756284820937115] [PMID: 33110448]
[51]
Shiota, S.; Reddy, R.; Alsarraj, A.; El-Serag, H.B.; Graham, D.Y. Antibiotic resistance of Helicobacter pylori among male United States veterans. Clin. Gastroenterol. Hepatol., 2015, 13(9), 1616-1624.
[http://dx.doi.org/10.1016/j.cgh.2015.02.005] [PMID: 25681693]
[52]
Mégraud, F.; Occhialini, A.; Rossignol, J.F. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob. Agents Chemother., 1998, 42(11), 2836-2840.
[http://dx.doi.org/10.1128/AAC.42.11.2836] [PMID: 9797212]
[53]
Abd-Elsalam, S.; Kobtan, A.; El-Kalla, F.; Elkhalawany, W.; Nawasany, S.E.; Saif, S.A.; Yousef, M.; Ali, L.A.; Soliman, S.; Mansour, L.; Habba, E.; Soliman, H.; Rizk, F.; Shehata, M.A. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. Medicine (Baltimore), 2016, 95(24)e3879
[http://dx.doi.org/10.1097/MD.0000000000003879] [PMID: 27310977]
[54]
Shehata, M.A.; Talaat, R.; Soliman, S.; Elmesseri, H.; Soliman, S.; Abd-Elsalam, S. Randomized controlled study of a novel triple nitazo-xanide (NTZ)-containing therapeutic regimen versus the traditional regimen for eradication of Helicobacter pylori infection. Helicobacter, 2017, 22(5)e12395
[http://dx.doi.org/10.1111/hel.12395] [PMID: 28524341]
[55]
Baylina, M.; Muñoz, N.; Sánchez-Delgado, J.; López-Góngora, S.; Calvet, X.; Puig, I. Systematic review: Would susceptibility-guided treatment achieve acceptable cure rates for second-line Helicobacter pylori therapy as currently practiced? Helicobacter, 2019, 24(3)e12584
[http://dx.doi.org/10.1111/hel.12584] [PMID: 30990575]
[56]
Lee, J.W.; Kim, N.; Nam, R.H.; Jang, J.Y.; Choi, Y.; Lee, D.H. Favorable outcomes of rescue second- or third-line culture-based Helico-bacter pylori eradication treatment in areas of high antimicrobial resistance. Helicobacter, 2021, 26(5)e12844
[http://dx.doi.org/10.1111/hel.12844] [PMID: 34382277]
[57]
Georgopoulos, S.D.; Ladas, S.D.; Karatapanis, S.; Triantafyllou, K.; Spiliadi, C.; Mentis, A.; Artikis, V.; Raptis, S.A. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. Aliment. Pharmacol. Ther., 2002, 16(3), 569-575.
[http://dx.doi.org/10.1046/j.1365-2036.2002.01220.x] [PMID: 11876712]
[58]
Matsumoto, Y.; Miki, I.; Aoyama, N.; Shirasaka, D.; Watanabe, Y.; Morita, Y.; Toyoda, M.; Mitani, T.; Miyachi, H.; Tamura, T.; Kasuga, M. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig. Liver Dis., 2005, 37(11), 821-825.
[http://dx.doi.org/10.1016/j.dld.2005.06.002] [PMID: 16040284]
[59]
Murakami, K.; Okimoto, T.; Kodama, M.; Sato, R.; Watanabe, K.; Fujioka, T. Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection. J. Clin. Gastroenterol., 2008, 42(2), 139-142.
[http://dx.doi.org/10.1097/MCG.0b013e31802cbc1a] [PMID: 18209581]
[60]
Murakami, K.; Sato, R.; Okimoto, T.; Nasu, M.; Fujioka, T.; Kodama, M.; Kagawa, J. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment. Pharmacol. Ther., 2003, 17(1), 119-123.
[http://dx.doi.org/10.1046/j.1365-2036.2003.01401.x] [PMID: 12492740]
[61]
Shimoyama, T.; Fukuda, S.; Mikami, T.; Fukushi, M.; Munakata, A. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. J. Gastroenterol., 2004, 39(10), 927-930.
[http://dx.doi.org/10.1007/s00535-004-1424-8] [PMID: 15549444]
[62]
Watanabe, Y.; Aoyama, N.; Shirasaka, D.; Maekawa, S.; Kuroda, K.; Miki, I.; Kachi, M.; Fukuda, M.; Wambura, C.; Tamura, T.; Kasuga, M. Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple thera-py. Dig. Liver Dis., 2003, 35(10), 711-715.
[http://dx.doi.org/10.1016/S1590-8658(03)00432-8] [PMID: 14620620]
[63]
Liang, C.M.; Cheng, J.W.; Kuo, C.M.; Chang, K.C.; Wu, K.L.; Tai, W.C.; Chiu, K.W.; Chiou, S.S.; Lin, M.T.; Hu, T.H.; Chuah, S.K. Levo-floxacin-containing second-line anti-Helicobacter pylori eradication in Taiwanese real-world practice. Biomed. J., 2014, 37(5), 326-330.
[http://dx.doi.org/10.4103/2319-4170.125650] [PMID: 25163495]
[64]
Losurdo, G.; Ierardi, E.; Di Leo, A. Helicobacter pylori antibiotic resistance: Stewardship, tailored therapies, and future perspectives. Gastroenterology, 2021, 161(3), 1071-1072.
[http://dx.doi.org/10.1053/j.gastro.2021.05.045] [PMID: 34048781]

Rights & Permissions Print Cite
Article Metrics
26
1
© 2024 Bentham Science Publishers | Privacy Policy